Clinical trials: Stroke Hemorrhagic
Stroke, Ischemic, Stroke Hemorrhagic
Transnasal Induction of Normothermia in Febrile Stroke Patients
The objective of this study is to evaluate safety and performance of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Fever, Seizures
- Trial name
- NCT03360656
- Testing
- Transnasal Thermal Regulating Device
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- CoolTech LLC
Stroke, Stroke, Acute
Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the ReWalk ReStore device in subjects with hemiplegia/hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis
- Trial name
- NCT03499210
- Testing
- ReWalk ReStore device
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- ReWalk Robotics, Inc.
Hydrocephalus, Hydrocephalus in Children
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
- Trial name
- NCT05397106
- Testing
- CODMAN CERTAS Plus Programmable Valve
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Integra LifeSciences Corporation
Stroke
Amplitude Modulation Frequency Comparison in Kilohertz Transcranial Magnetic Perturbation (kTMP) for Chronic Stroke
Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities.
- Trial name
- NCT07681102
- Testing
- kTMP
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Magnetic Tides
Intracerebral Hemorrhage, Stroke, Acute
A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage
The purpose of this research study is to find out whether a device for monitoring bleeding in patients with acute hemorrhagic stroke will show similar findings as CT scans performed to evaluate the stroke.
- Conditions
- Intracerebral Hemorrhage, Stroke, Acute, Stroke Hemorrhagic
- Trial name
- NCT03038087
- Testing
- SENSE Device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sense Diagnostics, LLC
Stroke, Hemorrhagic Strokes
Evaluation of Clinical Effectiveness and Safety of Locaste 8F Guiding Catheter in Neurovascular Interventional Surgery
The Locaste 8F Delivery Catheter by Kai MedTech has been launched in China since 2022 and has been widely used clinically. It won the government tendering in many provinces in China in early 2024.
- Trial name
- NCT06917248
- Where
- 2 sites in China
- Volunteers
- 113 people
- Sponsor
- Keuro MedTech
Stroke, Neurologic Diseases, General
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
- Trial name
- NCT00056238
- Testing
- NC-758 (Anti amyloidotic [Aß] agent)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bellus Health Inc. - a GSK company
Acute Cerebral Ischemia
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.
- Trial name
- FRONTIER (NCT02315443)
- Testing
- Nerinetide (NA-1)
- Where
- 4 sites in Canada
- Volunteers
- 532 people
- Sponsor
- NoNO Inc.
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Hemorrhage
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
This study is designed to validate implementation of the CRI algorithm in the CypherOx CRI system. Healthy human subjects will undergo progressive reduction in central blood volume to the point of hemodynamic instability (defined…
- Trial name
- NCT01935427
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Flashback Technologies
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Stroke, Acute, Intracranial Hemorrhages
Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet
The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects.
- Trial name
- NCT03495206
- Testing
- Y-2(Edaravone And Borneol) Sublingual Tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yantai YenePharma Co., Ltd.
Stroke, Ischemic, Stroke Hemorrhagic
Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis
- Trial name
- NCT03986320
- Testing
- Keeogo™ Dermoskeleton
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- B-Temia, Inc.
Stroke, Ischemic
A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke
This is a single centre、single arm、open-label，to investigate the safety and efficacy of EPC transplantation in the brain
- Trial name
- NCT03726814
- Testing
- EPC treatment group
- Volunteers
- 12 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Hemorrhagic Stroke, Ischemic Stroke
Early Feasibility Study of the SENSE Device
A single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset.
- Trial name
- NCT03827720
- Testing
- SENSE Device
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sense Diagnostics, LLC
Stroke, Ischemic, Stroke Hemorrhagic
Transnasal Induction of Normothermia for Neurogenic Fever
The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Seizures, Metabolic Encephalopathy
- Trial name
- NCT06038513
- Testing
- Transnasal Thermal Regulating Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- CoolTech LLC
Stroke
Pilot Study: A Novel Method of Non-Invasive Brain Stimulation (kTMP) to Enhance Motor Function in Chronic Stroke Patients
Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities.
- Trial name
- NCT06317194
- Testing
- kTMP
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Magnetic Tides
Stroke, Acute Stroke
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT07751328
- Testing
- Axana Scan and MRI
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wellumio R&D Australia Pty Ltd